Market research
BNTC Benitec Biopharma Ltd ADR
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 463M
- P/E ratio
- Not available
- Analyst target
- 24.1667
- Dividend yield
- Not available
- Beta
- 0.26
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US08205P2092
- Market cap
- 463M
- P/E ratio
- Not available
- Analyst target
- 24.1667
- Dividend yield
- Not available
- Beta
- 0.26
About
About Benitec Biopharma Ltd ADR
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the BNTC discussion.
5 years, 4 months ago
Benitec Biopharma Inc is currently in a long term uptrend where the price is trading 1.3% above its 200 day moving average.
From a valuation standpoint, the stock is 82.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 233.0.
Benitec Biopharma Inc's total revenue sank by 100.0% to $1 since the same quarter in the previous year.
Its net income has increased by 100.0% to $-3 since the same quarter in the previous year.
Finally, its free cash flow grew by 99.8% to $-6K since the same quarter in the previous year.
Based on the above factors, Benitec Biopharma Inc gets an overall score of 4/5.